Analyst Price Target is $55.13
▲ +70.03% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $55.13, with a high forecast of $67.00 and a low forecast of $48.00. The average price target represents a 70.03% upside from the last price of $32.42.
Current Consensus is
The current consensus among 8 investment analysts is to buy stock in Replimune Group. This Buy consensus rating has held steady for over two years.
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.